法律意见书 广东华商律师事务所 关于广西柳药集团股份有限公司 2025 年第二次临时股东会的 法律意见书 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会颁布的《上市公 司股东会规则》（以下简称"《股东会规则》"）等法律、行政法规、规范性文件， 以及《广西柳药集团股份有限公司章程》（以下简称"《公司章程》"）的规定， 广东华商律师事务所（以下简称"本所"）接受广西柳药集团股份有限公司（以 下简称"公司"）委托，指派本所律师出席公司 2025 年第二次临时股东会会议（以 下简称"本次股东会"），对本次股东会的相关事项进行见证，并据此出具本法律 意见书。 二〇二五年九月 中国 深圳 福田区 深南大道 4011 号香港中旅大厦 21-26 楼 法律意见书 广东华商律师事务所 关于广西柳药集团股份有限公司 2025 年第二次临时股东会的 法律意见书 致：广西柳药集团股份有限公司 本所同意将本法律意见书作为本次股东会的法定文件予以公告，并愿依法对 本所出具的法律意见承担相应的责任。 本所律师根据法律法规的有关要求，按照律师行业公认的业务 ...

| 证券代码：603368 | 证券简称：柳药集团 公告编号：2025-078 | | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | 广西柳药集团股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 252 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 117,977,356 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 30.3236 | 注：截至本次股东会股权登记日（2025 年 9 月 8 日），公司总股本为 397,168,905 股， 公司回购专用账户中已回购的股份 8,107,890 股没有表决权，故本次股东会有表决权的股份 总数为 389,061,015 股。 (四 ...

广西柳药集团股份有限公司 综上，公司董事会薪酬与考核委员会同意本次调整激励计划激励对象名单及 授予数量的事项。 董事会薪酬与考核委员会关于公司 2025 年股票期权激励计划 调整事项及激励对象名单（授予日）的核查意见 广西柳药集团股份有限公司（以下简称"公司"）董事会薪酬与考核委员会根 据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》 （以下简称"《证券法》"）《上市公司股权激励管理办法》（以下简称"《管理办法》"） 等有关法律、法规和规范性文件及《公司章程》的有关规定，对公司 2025 年股票 期权激励计划（以下简称"本激励计划"）调整事项及激励对象名单（授予日）进 行了必要核查，发表核查意见如下： （一）对调整本激励计划激励对象名单及授予数量的意见 公司本次对本激励计划激励对象名单及授予数量的调整符合《管理办法》等 法律、法规及规范性文件及《广西柳药集团股份有限公司 2025 年股票期权激励计 划（草案）》（以下简称"《激励计划》"）相关规定，审议程序合法、合规，不存 在损害公司股东利益的情形。调整后的激励对象符合相关法律法规规定的作为激 励对象的条件，主体资格合法、有效。 （ ...

二、董事会会议审议情况 经公司董事审议，会议表决通过了如下议案： （一）审议通过《关于调整 2025 年股票期权激励计划激励对象名单及授予 数量的议案》 鉴于公司 2025 年股票期权激励计划（以下简称"本激励计划"）所确定的 1 名激励对象被取消激励对象资格，公司董事会根据《广西柳药集团股份有限公 司 2025 年股票期权激励计划（草案）》（以下简称"《激励计划》"）有关规定和公 司 2025 年第二次临时股东会的授权，对本激励计划激励对象名单及授予数量进 行调整：本激励计划激励对象人数由 108 名调整为 107 名；本激励计划授予的股 票期权总量由 287.20 万份调整为 286.32 万份。 | 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-080 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 第五届董事会第二十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 广 ...

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]

Group 1 - The core viewpoint of the article is the strategic collaboration between Liu Pharmaceutical Group and Huawei Technologies, focusing on digital transformation in the pharmaceutical industry and the application of artificial intelligence [1] - The meeting aimed to discuss topics such as supply chain optimization and to further promote the implementation of their strategic partnership [1] - The collaboration seeks to establish a new benchmark for smart pharmaceuticals, indicating a significant shift towards technology integration in the healthcare sector [1]

Group 1 - The core viewpoint of the news is that Liuyao Group's stock has shown positive performance recently, with a notable increase in trading volume and a significant market capitalization of 7.419 billion yuan [1] - As of September 11, Liuyao Group's stock price increased by 2.02% to 18.68 yuan per share, with a trading volume of 1.07 billion yuan and a turnover rate of 1.47% [1] - The company has experienced a year-to-date stock price increase of 9.16%, with a 4.07% rise over the last five trading days and a 14.18% increase over the last 60 days [1] Group 2 - Liuyao Group's main business segments include wholesale (78.16%), retail (15.95%), and industrial (5.47%) operations, with other income contributing 0.42% [1] - As of June 30, the company reported a total revenue of 10.301 billion yuan for the first half of 2025, reflecting a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 429 million yuan, down 7.52% year-on-year [2] - The company has distributed a total of 1.789 billion yuan in dividends since its A-share listing, with 720 million yuan distributed over the past three years [3] Group 3 - As of June 30, the number of Liuyao Group's shareholders decreased to 32,900, a reduction of 0.89%, while the average number of circulating shares per person increased by 0.90% to 12,056 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 3.2792 million shares, a decrease of 1.1973 million shares compared to the previous period, while Southern CSI 1000 ETF increased its holdings by 0.8512 million shares to 2.9455 million shares [3]

Group 1 - The company announced the public disclosure of the list of incentive objects for the 2025 stock option incentive plan, which was approved in meetings held on August 28, 2025 [1][4] - The public disclosure period for the incentive objects was from August 29 to September 7, 2025, and no objections were received during this period [2][4] - The remuneration committee verified the qualifications of the incentive objects, confirming they met the necessary legal and regulatory requirements [3][6] Group 2 - The company will hold its second extraordinary general meeting of 2025 on September 15, 2025, using a combination of on-site and online voting [9][10] - The meeting will take place at the company's headquarters in Liuzhou, Guangxi, starting at 1:30 PM [11] - Shareholders must register in advance to attend the meeting, with specific registration times and methods outlined [24][25] Group 3 - The company has initiated a share repurchase program, with a total repurchase amount between RMB 100 million and RMB 200 million, and a maximum repurchase price of RMB 25.70 per share [35] - As of September 8, 2025, the company has repurchased 8.1079 million shares, representing 2.04% of the total share capital, with a total expenditure of RMB 148.4649 million [36][37] - The company will continue to comply with relevant regulations during the repurchase process and will disclose updates as necessary [39]

Group 1 - The company has announced the list of participants for its 2025 stock option incentive plan, which was approved by the board and supervisory committee [1][4] - The internal announcement regarding the incentive plan was made from August 29 to September 7, 2025, with no objections received during this period [2][1] - The compensation committee verified the eligibility of the incentive plan participants, confirming they meet the necessary legal and regulatory requirements [3][5] Group 2 - The company has initiated a share repurchase program, with a total repurchase amount set between RMB 100 million and RMB 200 million, and a maximum repurchase price of RMB 25.70 per share [7][9] - As of September 8, 2025, the company has repurchased 8.1079 million shares, representing 2.04% of the total share capital, with a total expenditure of approximately RMB 148.4649 million [9][10] - The company will continue to comply with relevant regulations during the share repurchase process and will disclose updates as necessary [11] Group 3 - The company will hold its second extraordinary general meeting of 2025 on September 15, 2025, utilizing both on-site and online voting methods [13][14] - The meeting will address several proposals that have already been approved by the board and supervisory committee [19][20] - Shareholders must register in advance to attend the meeting, with specific guidelines provided for both on-site and written registration [29][30]

Group 1 - The core point of the article is that Liu Pharmaceutical Group has announced a share buyback plan, with a total of 8.1079 million shares repurchased, representing 2.04% of the company's total share capital as of September 8, 2025 [1] - The share buyback has increased by 0.76% compared to the previous announcement [1] - The highest price for the repurchased shares was 18.60 yuan per share, while the lowest price was 17.83 yuan per share, with a total amount paid of 148.4649 million yuan (excluding transaction fees) [1]